In 2008, the first evidence of a new hormone called neuronostatin was published. The hormone was discovered using a bioinformatic method and found to originate from the same preprohormone as somatostatin. This small peptide hormone of 13 amino acids and a C-terminal amidation was soon found to exert pleiotropic physiological effects. In animal studies, neuronostatin has been shown to reduce food intake and delay gastric emptying and gastrointestinal transit. Furthermore, neuronostatin has been shown to affect glucose metabolism by increasing glucagon secretion during situations when glucose concentrations are low. Additionally, neuronostatin has been shown to affect neural tissue and cardiomyocytes by suppressing cardiac contractility. The effects of neuronostatin have not yet been delineated in humans, but if the effects found in animal studies translate to humans it could position neuronostatin as a promising target in the treatment of obesity, hypertension and diabetes. In this review, we describe the discovery of neuronostatin and the current understanding of its physiological role and potential therapeutic applicability.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Issue number4
Pages (from-to)R93-R101
Publication statusPublished - 1 Sep 2021


  • Animals
  • Appetite Regulation/drug effects
  • Diabetes Mellitus/genetics
  • Gastric Emptying/drug effects
  • Humans
  • Hypertension/genetics
  • Muscle Contraction/drug effects
  • Myocytes, Cardiac/drug effects
  • Neurons/drug effects
  • Obesity/genetics
  • Peptide Hormones/pharmacology
  • Signal Transduction/drug effects
  • Somatostatin/chemistry


Dive into the research topics of 'MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin'. Together they form a unique fingerprint.

Cite this